Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed to Participate at September Investor Conferences

Business Wire August 28, 2023

MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures

Business Wire August 14, 2023

MindMed Reports Second Quarter 2023 Financial Results and Business Highlights

Business Wire August 3, 2023

MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120

Business Wire August 3, 2023

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update

Business Wire July 31, 2023

Thinking about buying stock in Mind Medicine (MindMed), OPKO Health, Grange Resources, Hyzon Motors, or Bright Minds Biosciences?

PR Newswire July 14, 2023

MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Business Wire June 22, 2023

MindMed Announces Election of All Six Company Nominees at Annual Meeting

Business Wire June 21, 2023

MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day

Business Wire June 20, 2023

MindMed Adjourns Annual General Meeting of Shareholders

Business Wire June 15, 2023

MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline

Business Wire June 9, 2023

Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees

Business Wire June 8, 2023

MindMed to Host Investor Day June 2023

Business Wire June 7, 2023

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120

PR Newswire June 5, 2023

MindMed to Participate at Upcoming Investor Conferences

Business Wire June 1, 2023

MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders

Business Wire May 25, 2023

MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development Strategy

Business Wire May 25, 2023

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting

Business Wire May 24, 2023

MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Business Wire May 17, 2023

MindMed Reports First Quarter 2023 Financial Results and Business Highlights

Business Wire May 4, 2023